

Michele Orditura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1967160/publications.pdf>

Version: 2024-02-01

115
papers

5,227
citations

81889

39
h-index

91872

69
g-index

117
all docs

117
docs citations

117
times ranked

7998
citing authors

#	ARTICLE	IF	CITATIONS
1	An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 646.	3.7	5
2	Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 813462.	2.8	2
3	Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series. <i>Healthcare (Switzerland)</i> , 2022, 10, 708.	2.0	4
4	Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice. <i>Cancers</i> , 2022, 14, 2102.	3.7	12
5	Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 110-113.	2.5	3
6	Cancer Treatmentâ€“Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 45.	3.0	20
7	Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. <i>Scientific Reports</i> , 2020, 10, 18190.	3.3	16
8	PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. <i>Frontiers in Oncology</i> , 2020, 10, 782.	2.8	11
9	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. <i>Cancers</i> , 2020, 12, 819.	3.7	61
10	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania â€“Luigi Vanvitelliâ€™. <i>ESMO Open</i> , 2020, 5, e000675.	4.5	11
11	Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2814.	4.1	18
12	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020, 11, 2083-2091.	1.8	7
13	<p>Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 867-876.	2.0	8
14	Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer. <i>Scientific Reports</i> , 2019, 9, 16131.	3.3	19
15	Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 314-323.	1.4	3
16	Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 178.	8.6	28
17	Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. <i>Cancers</i> , 2019, 11, 399.	3.7	46
18	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. <i>Frontiers in Oncology</i> , 2019, 9, 1289.	2.8	10

#	ARTICLE	IF	CITATIONS
19	PARP inhibitors in ovarian cancer. <i>Cancer Treatment Reviews</i> , 2019, 73, 1-9.	7.7	158
20	Indocyanine Green Fluorescence Imaging-Guided Surgery in Primary and Metastatic Liver Tumors. <i>Surgical Innovation</i> , 2018, 25, 62-68.	0.9	41
21	What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2659.	4.1	41
22	Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy. <i>Future Oncology</i> , 2018, 14, 2493-2505.	2.4	15
23	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). <i>Targeted Oncology</i> , 2018, 13, 469-479.	3.6	38
24	Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. <i>Current Oncology Reports</i> , 2018, 20, 76.	4.0	72
25	Propensity score-matched comparison between complete mesocolic excision and classic right hemicolectomy for colon cancer. <i>Minerva Surgery</i> , 2018, 73, 1-12.	0.6	5
26	Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. <i>Medical Oncology</i> , 2017, 34, 186.	2.5	7
27	Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1764-1774.	1.7	49
28	Naples Prognostic Score, Based on Nutritional and Inflammatory Status, is an Independent Predictor of Long-term Outcome in Patients Undergoing Surgery for Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 1273-1284.	1.3	100
29	Pancreatic stump closure after pancreatoduodenectomy in elderly patients: a retrospective clinical study. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 35-40.	2.9	42
30	Phosphatidylinositol 3-kinase (PI3K)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 76479-76491.	1.8	24
31	Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience. <i>PLoS ONE</i> , 2017, 12, e0173619.	2.5	16
32	Metformin increases antitumor activity of MEK inhibitors through GIL1 downregulation in LKB1 positive human NSCLC cancer cells. <i>Oncotarget</i> , 2016, 7, 4265-4278.	1.8	58
33	Does Preoperative Neutrophil to Lymphocyte Ratio Predict Disease-Free Survival Rate in Colorectal Cancer Patients Undergoing Curative Surgery?. <i>Annals of Surgery</i> , 2016, 263, e80.	4.2	0
34	Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. <i>ESMO Open</i> , 2016, 1, e000038.	4.5	66
35	Pancreatic neuroendocrine tumors: Nosography, management and treatment. <i>International Journal of Surgery</i> , 2016, 28, S156-S162.	2.7	42
36	Mediastinal sarcoid-like reaction after colon adenocarcinoma resection. <i>Asian Cardiovascular and Thoracic Annals</i> , 2015, 23, 82-84.	0.5	7

#	ARTICLE	IF	CITATIONS
37	Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. Surgery, 2015, 157, 285-296.	1.9	49
38	Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review. International Journal of Surgery, 2015, 21, S10-S14.	2.7	21
39	CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence. Oncology Letters, 2015, 9, 542-550.	1.8	18
40	Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. Oncology Letters, 2015, 9, 1403-1405.	1.8	4
41	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncology Letters, 2015, 9, 1628-1632.	1.8	25
42	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncology, The, 2015, 16, 561-568.	10.7	141
43	Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis. Surgery, 2015, 158, 112-120.	1.9	71
44	Reply “Modified D2 lymphadenectomy is effective in patients with node-positive gastric cancers undergoing potentially curative total gastrectomy” Surgery, 2015, 158, 1447-1448.	1.9	1
45	Treatment of esophagogastric junction carcinoma: An unsolved debate. World Journal of Gastroenterology, 2015, 21, 4427-4431.	3.3	4
46	Treatment of gastric cancer. World Journal of Gastroenterology, 2014, 20, 1635.	3.3	508
47	Effect of Preoperative Chemoradiotherapy on Outcome of Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma” A Pilot Study. Current Oncology, 2014, 21, 125-133.	2.2	13
48	Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. International Journal of Colorectal Disease, 2014, 29, 89-97.	2.2	107
49	MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).. Journal of Clinical Oncology, 2014, 32, 5503-5503.	1.6	9
50	Clinical management of advanced gastric cancer: The role of new molecular drugs. World Journal of Gastroenterology, 2014, 20, 14537.	3.3	41
51	Incidence and prognostic significance of HER2 overexpression in gastric cancer (GC): A monoinstitutional retrospective analysis.. Journal of Clinical Oncology, 2014, 32, 160-160.	1.6	0
52	Postoperative chemoradiation FOLFOX 4-based for R1 resected gastric cancer: A retrospective mono-institutional study.. Journal of Clinical Oncology, 2014, 32, 143-143.	1.6	0
53	Increased circulating levels of VEGF-C to predict outcome in resectable gastric cancer patients.. Journal of Clinical Oncology, 2014, 32, 4080-4080.	1.6	0
54	Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.. Journal of Clinical Oncology, 2014, 32, e15257-e15257.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Correlation of 12-weeks decrease of CA19.9 with overall response rate (ORR) and progression-free survival (PFS) in advanced pancreatic cancer (APC) patients (pts) treated with first-line nab-paclitaxel (Nab-P) and gemcitabine (G).. Journal of Clinical Oncology, 2014, 32, e15256-e15256.	1.6	0
56	Postoperative Detection of Circulating Tumor Cells Predicts Tumor Recurrence in Colorectal Cancer Patients. Journal of Gastrointestinal Surgery, 2013, 17, 1809-1818.	1.7	45
57	Emerging VEGF-receptor inhibitors for colorectal cancer. Expert Opinion on Emerging Drugs, 2013, 18, 25-37.	2.4	26
58	Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines. Clinical Cancer Research, 2013, 19, 3508-3519.	7.0	106
59	Preoperative treatment of locally advanced esophageal carcinoma. International Journal of Oncology, 2013, 43, 1745-1753.	3.3	8
60	Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. Oncology Reports, 2013, 30, 2992-2998.	2.6	11
61	Critical appraisal of the use of regorafenib in the management of colorectal cancer. Cancer Management and Research, 2013, 5, 49.	1.9	5
62	Radiofrequency-Assisted Liver Resection With a Comb-Shaped Bipolar Device Versus Clamp Crushing. Surgical Innovation, 2012, 19, 407-414.	0.9	6
63	Combined CD133/CD44 Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer. Archives of Surgery, 2012, 147, 18.	2.2	68
64	Impact of Total Fundoplication on Esophageal Transit. Journal of Clinical Gastroenterology, 2012, 46, e1-e5.	2.2	26
65	Current status of targeted therapies in advanced gastric cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S29-S34.	3.4	35
66	Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. Expert Opinion on Investigational Drugs, 2012, 21, 949-959.	4.1	21
67	The Over-The-Scope-Clip (OTSC) System is Effective in the Treatment of Chronic Esophagojejunal Anastomotic Leakage. Journal of Gastrointestinal Surgery, 2012, 16, 1585-1589.	1.7	35
68	Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. Ecological Management and Restoration, 2012, 25, 130-136.	0.4	20
69	Targeting EGFR in Pancreatic Cancer Treatment. Current Drug Targets, 2012, 13, 802-810.	2.1	121
70	Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors. PLoS ONE, 2011, 6, e28841.	2.5	40
71	A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. British Journal of Cancer, 2011, 104, 427-432.	6.4	42
72	Behavior of Circulating CD4+CD25+Foxp3+ Regulatory T Cells in Colon Cancer Patients Undergoing Surgery. Journal of Clinical Immunology, 2011, 31, 1095-1104.	3.8	38

#	ARTICLE	IF	CITATIONS
73	Endoscopic Intraoperative Anastomotic Testing May Avoid Early Gastrointestinal Anastomotic Complications. A Prospective Study. Journal of Gastrointestinal Surgery, 2011, 15, 145-152.	1.7	25
74	Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. BMC Cancer, 2011, 11, 126.	2.6	22
75	Trastuzumab Resistance in Breast Cancer. , 2011, , 51-60.		0
76	Adjuvant Chemoradiotherapy in Patients With Stage III or IV Radically Resected Gastric Cancer. Archives of Surgery, 2010, 145, 233.	2.2	17
77	Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study. Cancer Investigation, 2010, 28, 820-827.	1.3	18
78	Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells. Clinical Cancer Research, 2010, 16, 4990-5001.	7.0	79
79	Perspectives in Adjuvant Therapy of Gastric Cancer. Oncology, 2009, 77, 38-42.	1.9	17
80	Novel investigational drugs for gastric cancer. Expert Opinion on Investigational Drugs, 2009, 18, 945-955.	4.1	17
81	The Lymph Node Ratio Is a Powerful Prognostic Factor of Node-Positive Colon Cancers Undergoing Potentially Curative Surgery. World Journal of Surgery, 2009, 33, 2704-2713.	1.6	38
82	Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis. Oncology Reports, 2009, 21, 1023-8.	2.6	48
83	Prognostic Biomarkers and Targeted Therapy in Gastric Cancer: Reply. World Journal of Surgery, 2008, 32, 1227-1229.	1.6	6
84	Complete pathological response of colorectal liver metastases after chemotherapy and bevacizumab treatment: a case report. Targeted Oncology, 2008, 3, 253-258.	3.6	2
85	Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients. Annals of Surgical Oncology, 2008, 15, 69-79.	1.5	220
86	Integrated Therapy in Localized Gastric Cancer: Targeted and Tailored Approach. Annals of Surgical Oncology, 2008, 15, 2983-2985.	1.5	1
87	First-Line Chemotherapy vs Bowel Tumor Resection Plus Chemotherapy for Patients With Unresectable Synchronous Colorectal Hepatic Metastases. Archives of Surgery, 2008, 143, 352.	2.2	114
88	Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM) Tj ETQq0 010rgBT /Owrlck 10	1.2	10
89	Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 242-248.	0.3	0
90	Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass. World Journal of Surgical Oncology, 2007, 5, 42.	1.9	11

#	ARTICLE	IF	CITATIONS
91	Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. <i>Oncogene</i> , 2007, 26, 3654-3660.	5.9	140
92	Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery. <i>World Journal of Surgery</i> , 2007, 31, 1458-1468.	1.6	140
93	Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report. <i>Targeted Oncology</i> , 2007, 2, 253-257.	3.6	0
94	Capecitabine Plus Weekly Oxaliplatin in Gastrointestinal Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 85-89.	1.3	2
95	Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery. <i>Annals of Surgical Oncology</i> , 2006, 13, 823-835.	1.5	104
96	p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. <i>Journal of Surgical Oncology</i> , 2006, 93, 241-252.	1.7	35
97	Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. <i>Annals of Oncology</i> , 2006, 17, 1529-1532.	1.2	14
98	A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. <i>British Journal of Cancer</i> , 2005, 92, 1644-1649.	6.4	171
99	Cetuximab in the treatment of colorectal cancer. <i>Future Oncology</i> , 2005, 1, 173-181.	2.4	17
100	Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas. <i>Clinical Cancer Research</i> , 2004, 10, 3490-3499.	7.0	103
101	Prognostic Value of p27, p53, and Vascular Endothelial Growth Factor in Dukes A and B Colon Cancer Patients Undergoing Potentially Curative Surgery. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 1904-1914.	1.3	30
102	Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. <i>Cancer</i> , 2004, 100, 270-278.	4.1	100
103	The role of EGFR inhibitors in nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2004, 16, 130-135.	2.4	91
104	Normal Interleukin-10 Serum Level Opposed to High Serum Levels of Carbohydrate Antigen 19-9 and Cancer Antigens 125 and 50 in a Case of True Splenic Cyst. <i>Archives of Medical Research</i> , 2003, 34, 145-148.	3.3	12
105	Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 501-514.	2.4	27
106	A True Splenic Cyst Producing Carbohydrate Antigen 19-9 and Cancer Antigens 50 and 125, but Not Interleukin 10. <i>Digestive Surgery</i> , 2003, 20, 71-74.	1.2	7
107	Elevated Serum Levels of Interleukin-8 in Advanced Non-Small Cell Lung Cancer Patients: Relationship with Prognosis. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 1129-1135.	1.2	70
108	Preoperative Chemoradiotherapy for Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus. <i>Chest</i> , 2002, 122, 1302-1308.	0.8	52

#	ARTICLE	IF	CITATIONS
109	Prognostic Significance of Circulating IL-10 and IL-6 Serum Levels in Colon Cancer Patients Undergoing Surgery. Clinical Immunology, 2002, 102, 169-178.	3.2	196
110	Circulating Levels of Interleukin-10 and Interleukin-6 in Gastric and Colon Cancer Patients Before and After Surgery: Relationship with Radicality and Outcome. Journal of Interferon and Cytokine Research, 2002, 22, 473-482.	1.2	60
111	Interleukin-6 Serum Level Correlates with Survival in Advanced Gastrointestinal Cancer Patients but Is Not an Independent Prognostic Indicator. Journal of Interferon and Cytokine Research, 2001, 21, 45-52.	1.2	76
112	Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunology, Immunotherapy, 2000, 49, 530-536.	4.2	51
113	Serum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients. Chest, 2000, 117, 365-373.	0.8	139
114	Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. , 1999, 86, 1936-1943.		75
115	Adult Wilms' tumor. , 1997, 80, 1961-1965.		27